Cladribine
Active ingredient · 2 therapeutic classes
Sold as Litak · Movectro · MAVENCLAD
- Drug class
- Purine Analogues
- Availability
- See label
- Routes
- Oral, Intravenous
- Markets covered
- 3
- Products on record
- 14
Overview
Cladribine is an active pharmaceutical ingredient in the Purine Analogues group (L01BB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 7 | May 15, 2026 |
| CA Canada | Health Canada | 5 | March 18, 2026 |
| EU European Union | EMA | 2 | January 13, 2026 |
GBUnited Kingdom· MHRA
7 products
Uses
Cladribine Merck is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease as defined by clinical or imaging features.
How to take
CACanada· Health Canada
5 products
Uses
MAVENCLAD (cladribine) is indicated as monotherapy for the treatment of adult patients with relapsing- remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability. MAVENCLAD is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, one or more therapies for multiple sclerosis.
MAVENCLAD treatment should be initiated and supervised by neurologists experienced in the treatment of MS and who have fully familiarized themselves with the efficacy and safety profile of MAVENCLAD and are able to discuss benefits/risks with patients.
The efficacy of taking MAVENCLAD for treatment duration beyond 2 years has not been established. 1 Pediatrics (< 18 years of age) No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
4, Geriatrics).
EUEuropean Union· EMA
2 products
Uses
1).
How to take
Drug interactions
Known interactions involving Cladribine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 295. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB116480272 · revised March 13, 2026
- [2]Health Canada (DPD) · 02470179 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/004230 · revised January 13, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.